HomeHealthcare & Life SciencesPharmaceuticals Hepatic Encephalopathy Treatment Market

South Africa Hepatic Encephalopathy Treatment Market Size & Outlook, 2026-2034


South Africa Hepatic Encephalopathy Treatment Market Insights

  • As per Reed Intelligence insights, the South Africa Hepatic Encephalopathy Treatment Market stood at USD 28.52 Million in 2025 and is anticipated to grow to USD 62.01 Million by 2034.
  • The South Africa market is expected to advance at a CAGR of 9.02% from 2026 through 2034.
  • In 2025, Rifaximin accounted for the highest share of the Drug Class market size.
  • During the forecast period, L-ornithine L-aspartate is set to register the highest growth, making it the most lucrative Drug Class segment.

Other Key Findings


  • As of 2025, South Africa held 1.15% of the global Hepatic Encephalopathy Treatment Market size.
  • By 2034, United States is anticipated to capture the largest share of the global Hepatic Encephalopathy Treatment Market.
  • In Middle East and Africa, United Arab Emirates is expected to lead the regional Hepatic Encephalopathy Treatment Market size by 2034.
  • Turkey will remain the fastest-growing market in Middle East and Africa, reaching USD 38.95 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 28.52 Million
Market Size In 2034 USD 62.01 Million
Largest segment Rifaximin
Units Revenue in USD Million
CAGR 9.02% (2026-2034)
Segmnetation Covered
Drug Class
  1. Rifaximin
  2. Lactulose
  3. L-ornithine L-aspartate
  4. Antibiotics
  5. Microbiome-based Therapies
Disease Type
  1. Overt Hepatic Encephalopathy
  2. Minimal Hepatic Encephalopathy
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Related Reports